A judge in the high-stakes trial over the $420 million sale of Viterra’s Joe White malt business to Cargill has denied Cargill’s request to have settlement talks admitted as evidence, shooting down the agricultural giant’s argument that the talks were needed to challenge Glencore in-house counsel’s assertion that he is of good character and will not breach a confidentiality agreement.
Generic drug makers Arrow and Apotex have won the ACCC’s blessing for a tie-up that will create the largest generic drug supplier in Australia, with the competition regulator saying the deal will not substantially lessen competition.
A Melbourne retailer is challenging a $2.8 million fine against it for allegedly violating the intellectual property for Microsoft’s Windows 7 software.
Cricket Australia has reached a settlement in a lawsuit filed by a Tasmanian woman who was fired by the sports league for tweeting her views about abortion.
A patent for genome editing technology by a South Korean biotechnology company has been rejected for a lack of clarity, novelty, and inventiveness, but the Australian Patent Office has given the company two months to try again.
The Australian Securities and Investments Commission failed to establish any grounds for permanently banning an ANZ financial adviser from the industry, a tribunal said in setting aside the decision Tuesday.
The Full Federal Court has overturned a win for the consumer regulator in a case against Sydney-based Unique International College, ruling that the vocational trainer’s practices for marketing and enrolling students in its diploma courses did not amount to unconscionable conduct.
A judge has agreed to sign off on an order in a massive class action against Westpac that could give 25 percent of any recovery to the litigation funder underwriting the case, on the condition that the funder accept a rate reflecting the net, not the gross, sum.
Bega has admitted to allegations by Kraft that it distributed its peanut butter in boxes with the Kraft logo on the outside, but says it was allowed to under a license agreement.
Generic drug company Alphapharm has lost a bid for documents it claimed would show Sanofi-Aventis suspected as early as 2015 that patents for one of its injector pens may be invalid.